Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis
Journal of Extracellular Vesicles · 2025-06 · 14 (6)
DOI: 10.1002/jev2.70099 ↗At a glance
Journal article in Journal of Extracellular Vesicles, published online on 2025-06-23. Written by Zhuo Chen and 8 co-authors. Institution: Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The…. Major MEDLINE topics: Extracellular Vesicles, Mesenchymal Stem Cells, Atherosclerosis, Epithelial-Mesenchymal Transition. Cited 15 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The National Natural Science Foundation of China, Chongqing Natural Science Foundation, Chongqing Medical Scientific Research Project.
Abstract (original language)
Endothelial–mesenchymal transition (EndMT) of vascular endothelial cells (VECs) plays a pivotal role in the progression of atherosclerosis (AS). The therapeutic potential of reversing EndMT holds promise for AS treatment. In this study, bone marrow mesenchymal stem cells (BMSCs)–derived extracellular vesicles (EVs) are engineered as nanostructured drug carriers with two functional modules, targeting module and functional protein module. In targeting module, to specifically target VECs, the cholesterol‐modified aptamers of VECs‐specific protein vascular endothelial growth factor (VEGF) are assembled to the engineered EVs. In functional protein module, engineered EVs are infected with recombinant silent information regulator 2–related enzyme 1 (SIRT1) adenoviruses, with the achievement of SIRT1 protein overexpression on the surface. Upon targeted aggregation around the mesenchymalized VECs, the engineered EVs are taken up by VECs and the loaded SIRT1 is released into VECs. Then, SIRT1 can effectively reverse VECs‐EndMT by activating nuclear factor‐erythroid 2–related factor 2 (Nrf2) and regulating oxidative stress response. The targeted efficacy for precision therapy in AS has been successfully demonstrated both in vitro and in vivo, by reversing EndMT and reducing inflammation in atherosclerotic plaques. This study provides a novel strategy for AS treatment and offers insights into the next generation of regenerative medicine technologies based on engineered EVs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Rehabilitation Medicine, Key Laboratory of Physical Medicine and Precision Rehabilitation of Chongqing Municipal Health Commission, The First Affiliated Hospital of Chongqing Medical University, Chongqing,…
- Department of Clinical Laboratory Medicine, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
- Army 953th Hospital (Shigatse Branch, Xinqiao Hospital), Third Military Medical University, Shigatse, China.
Funding
- The National Natural Science Foundation of China
- Chongqing Natural Science Foundation
- Chongqing Medical Scientific Research Project
Cite
APA
Chen, Z., Chang, K., Yang, S., Deng, R., He, Y., Zhang, L., Chen, M., Bai, D., & Pi, Y. (2025). Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles, 14(6). https://doi.org/10.1002/jev2.70099
Vancouver
Chen Z, Chang K, Yang S, Deng R, He Y, Zhang L, et al. Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis. Journal of Extracellular Vesicles. 2025;14(6). doi:10.1002/jev2.70099
BibTeX
@article{Chen2025,
author = {Chen, Zhuo and Chang, Kai and Yang, Sha and Deng, Ruijia and He, Yuan and Zhang, Ligai and Chen, Ming and Bai, Dingqun and Pi, Yan},
title = {Engineered Mesenchymal Stem Cell–Derived Extracellular Vesicles Reverse Endothelial–Mesenchymal Transition in Atherosclerosis},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {6},
doi = {10.1002/jev2.70099}
}
EUVIMED